NCT07033481

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: EIP Pharma Inc · Industry
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Conditions

• Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Interventions

Type	Name	Description
DRUG	Neflamapimod	Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules
DRUG	Placebo	Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Timeline

• Start date: 2025-10-02
• Primary completion: 2026-09-01
• Completion: 2026-10-01
• First posted: 2025-06-24
• Last updated: 2026-04-08

Locations

5 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study